News of Note—Sun Pharma slapped with Form 483; Catalent invests $14M; FDA draft guidance


> Sun Pharmaceutical has been issued a Form 483 with 11 observations for its plant in Dadra, India. Story

> Somerset, New Jersey-based Catalent is investing $14 million to expand softgel capabilities at its facility in Eberbach, Germany, in response to demand for animal-free consumer health products. Release

> The FDA has issued new draft guidance for how companies should handle voluntary recalls. Release

> East Rutherford, New Jersey-based CDMO Cambrex has opened a new 120-square-meter quality control laboratory at its site in Milan, Italy. Release